Aptamers Market Latest Innovation in 2019 by SOMALOGIC, APTAMER GROUP, APTAMER SCIENCES, BASE PAIR BIOTECHNOLOGIES, NOXXON PHARMA, VIVONICS, APTAGEN

The global Aptamers market has been estimated to reach USD 401.30 million in 2023. The market is expected to register a CAGR of 17.89% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16739
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Advancements in the field of aptamer development technologies
Advancements in aptamer development technologies, increasing R&D, and rising number of companies investing in this market are some of the key driving factors responsible for the growth of this market. Numerous advantages offered by these small molecules in comparison to established antibodies have also led to higher demand for these molecules across a diverse range of medical applications. They are chemically synthesized, which eliminates batch-to-batch variation and demands less time for development. Along with this, continuous advancement in technologies is expected to stimulate growth.

Key developments in the market
• In November, 2017, Base Pair Biotechnologies has closed a $3.2 million Series A-3 financing round. Base Pair provides custom aptamer discovery and development services, as well as a line of catalog aptamers. The company said it would use the financing to acquire new lab instruments and other technology in order to to expand its cellular and molecular analysis capabilities, as well as to expand its team.
• In December, 2017, Caris Life Sciences Identifies New Mechanism of Action for an Aptamer with Therapeutic Potential to Treat Non-Hodgkin Lymphoma

Major key players:
SOMALOGIC, INC, APTAMER GROUP, APTAMER SCIENCES, INC., BASE PAIR BIOTECHNOLOGIES, INC., NOXXON PHARMA, VIVONICS INC., APTAGEN, LLC etc.

Request Discount on this report @ https://marketprognosis.com/discount-request/16739
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Low awareness level and incomplete regulatory policies slow down the market growth
Many aptamers have failed to meet the requisite safety and efficacy standards in clinical studies. Thus, companies have to terminate the clinical investigation during late-stage clinical studies. This factor is likely to affect growth of this market negatively. In addition, other factors such as low awareness about these technologies in middle- & low-income countries and inadequate regulatory structure may hamper the overall growth.

North America to Dominate the Market
The Aptamers market is segmented by type of treatment and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America. North America dominates the Aptamers market due to the increasing technological advancements and high investment & funding to support development of Aptamers. Asia-Pacific is also expected to propel the Aptamers market owing to factors, such as increasing research and development activities and economic growth.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/16739
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.